Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €68.39 EUR
Change Today +0.39 / 0.57%
Volume 9.5K
TUB On Other Exchanges
EN Brussels
As of 11:35 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

financiere de tubize (TUB) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/27/15 - €68.45
52 Week Low
08/24/15 - €49.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for FINANCIERE DE TUBIZE (TUB)

Related News

No related news articles were found.

financiere de tubize (TUB) Related Businessweek News

No Related Businessweek News Found

financiere de tubize (TUB) Details

Financière de Tubize SA/NV, through its interest in UCB SA/NV, operates as a biopharmaceutical company worldwide. The company is involved in the discovery and development of medicines and solutions in the therapeutic areas of central nervous system and immunology system. Its central nervous system products comprise Keppra that is used to treat partial onset seizures in adults, adolescents, children, and infants; Neupro for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease, as well as idiopathic restless legs syndrome in adults; Metadate CD to treat attention deficit hyperactivity disorder; Nootropil for the treatment of vertigo and events associated with ageing; Xyrem, a sodium oxybate drug for narcolepsy with cataplexy in adult patients; and Vimpat, which is used as adjunctive therapy for the treatment of partial-onset seizures. The company’s immunology system products include Cimzia for the treatment of ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, psoriatic arthritis, and rheumatoid arthritis; Xyzal for treating allergic rhinitis, including persistent allergic rhinitis and chronic idiopathic urticaria; Zyrtec, an antihistamine for the symptomatic treatment of seasonal allergic rhinitis, perennial rhinitis, and chronic idiopathic urticaria; Tussionex for relief of cough and upper respiratory symptoms; and Lortab for the relief of severe pain. Financière de Tubize SA/NV is based in Brussels, Belgium.

financiere de tubize (TUB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

financiere de tubize (TUB) Key Developments

Financière De Tubize S.A. Reports Consolidated Earnings Results for the First Half of June 30, 2015

Financière de Tubize S.A. reported consolidated earnings results for the first half of June 30, 2015. For the period, the company reported profit before taxes of EUR 86,824,000 compared to EUR 41,422,000 a year ago. Profit was EUR 89,632,000 compared to EUR 41,449,000 a year ago. Profit attributable to owners of the parent of EUR 89,632,000 compared to EUR 41,449,000 a year ago. Basic and diluted earnings per share were EUR 2.01 compared to EUR 0.93 a year ago. Cash flow from operating activities was EUR 331,000 compared to EUR 315,000 a year ago.

Financière de Tubize S.A. Reports Non-Consolidated and Consolidated Earnings Results for the First Half Ended June 30, 2015

Financiere de Tubize SA reported non-consolidated and consolidated earnings results for the first half ended June 30, 2015. On non-consolidated basis, profit was EUR 65.5 million. On consolidated basis, profit was EUR 89.6 million.

Financière de Tubize S.A. to Report First Half, 2015 Results on Jul 31, 2015

Financière de Tubize S.A. announced that they will report first half, 2015 results on Jul 31, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TUB:BB €68.39 EUR +0.39

TUB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TUB.
View Industry Companies

Industry Analysis


Industry Average

Valuation TUB Industry Range
Price/Earnings 26.5x
Price/Sales -- Not Meaningful
Price/Book 1.6x
Price/Cash Flow 26.5x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact FINANCIERE DE TUBIZE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at